The role of thalidomide for previously untreated elderly patients with multiple myeloma
remains unclear. Six randomized controlled trials, launched in or after 2000, compared …

Abstract Treatment with melphalan-prednisone-thalidomide improves the outcome of
patients with multiple myeloma and is now considered a standard of care for patients not …

Purpose For several decades, the treatment of elderly patients with multiple myeloma (MM)
has consisted of melphalan and prednisone (MP). The Dutch-Belgium Hemato-Oncology …

Background Since 1960, oral melphalan and prednisone (MP) has been regarded as the
standard of care in elderly multiple myeloma patients. This multicentre randomised trial …

Purpose Until recently, melphalan and prednisone were the standards of care in elderly
patients with multiple myeloma. The addition of thalidomide to this combination …

We compared thalidomide-dexamethasone (TD) with melphalan-prednisolone (MP) in 289
elderly patients with multiple myeloma (MM). Patients received either thalidomide 200 mg …

Trials comparing efficacy of melphalan prednisone (MP) with MP plus thalidomide in
transplant ineligible, elderly patients with multiple myeloma have provided conflicting …

The initial analysis of the oral combination melphalan, prednisone, and thalidomide (MPT) in
newly diagnosed patients with myeloma showed significantly higher response rate and …

A systematic review and meta-analysis was performed to determine the efficacy and toxicity
of thalidomide in previously untreated patients with myeloma. Medline, Embase, Cochrane …

Thalidomide maintenance has the potential to modulate residual multiple myeloma (MM)
after an initial response. This trial compared the effect of thalidomide maintenance and no …